[HTML][HTML] New PET radiotracers for the imaging of neuroendocrine neoplasms

E Fortunati, G Argalia, L Zanoni, S Fanti… - … treatment options in …, 2022 - Springer
Opinion statement Neuroendocrine neoplasms (NEN) are a heterogeneous group of
tumours derived from cells of neuroendocrine origin and can potentially arise everywhere in …

[HTML][HTML] CXCR4-targeted theranostics in oncology

AK Buck, SE Serfling, T Lindner, H Hänscheid… - European Journal of …, 2022 - Springer
A growing body of literature reports on the upregulation of CXC motif chemokine receptor 4
(CXCR4) in a variety of cancer entities, rendering this receptor as suitable target for …

Imaging of CXC motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-pentixafor PET

AK Buck, A Haug, N Dreher, A Lambertini… - Journal of Nuclear …, 2022 - Soc Nuclear Med
In recent years, molecular imaging addressing the CXC motif chemokine receptor 4
(CXCR4) has increasingly been used in various clinical settings. Here, we aimed to assess …

Molecular imaging theranostics of neuroendocrine tumors

E Fortunati, N Bonazzi, L Zanoni, S Fanti… - Seminars in Nuclear …, 2023 - Elsevier
Neuroendocrine neoplasms (NEN) are rare and heterogeneous tumors, originating mostly
from the gastro-entero-pancreatic (GEP) tract followed by the lungs. Multidisciplinary …

[HTML][HTML] Impact of CXCR4-directed PET/CT on staging and proposed oncologic management in patients with digestive system tumors

A Weich, SE Serfling, W Schlötelburg… - Clinical nuclear …, 2023 - journals.lww.com
Purpose To elucidate the influence of CXC motif chemokine receptor 4 (CXCR4)–directed
imaging on staging and proposed oncologic management in patients with digestive system …

[HTML][HTML] CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology

N Dreher, S Hahner, CT Fuß, W Schlötelburg… - European Journal of …, 2024 - Springer
Background CXC motif chemokine receptor 4 (CXCR4) is overexpressed in various solid
cancers and can be targeted by CXCR4-directed molecular imaging. We aimed to …

[HTML][HTML] Interobserver agreement rates on CXC Motif chemokine receptor 4–directed molecular imaging and therapy

PE Hartrampf, A Kosmala, SE Serfling… - Clinical nuclear …, 2023 - journals.lww.com
Background We aimed to evaluate the interobserver agreement rates in patients scanned
with CXC motif chemokine receptor 4 (CXCR4)–directed PET/CT, including the rate of …

Nuclear medicine application of pentixafor/pentixather targeting CXCR4 for imaging and therapy in related disease

Z Chen, Q Xue, S Yao - Mini Reviews in Medicinal Chemistry, 2023 - ingentaconnect.com
CXC-motif chemokine receptor 4 (CXCR4) is a novel predictive biomarker for metastasis
and poor prognosis in individuals with malignancies. CXCL12 is the only cognate ligand of …

[HTML][HTML] Current Status of 68Ga-Pentixafor in Solid Tumours

B Hadebe, MM Sathekge, C Aldous, M Vorster - Diagnostics, 2022 - mdpi.com
Chemokine receptor CXCR4 is overexpressed in neoplasms and its expression is related to
tumour invasion, metastasis and aggressiveness. 68Ga-Pentixafor is used to non-invasively …

Chemokine receptor PET imaging: Bridging molecular insights with clinical applications

C Hunter, B Larimer - Nuclear Medicine and Biology, 2024 - Elsevier
Chemokine receptors are important components of cellular signaling and play a critical role
in directing leukocytes during inflammatory reactions. Their importance extends to numerous …